Home > Business Cases > In-licensing decisions
In-licensing decisions
-
European BioPharma, model based in-licensing.
-
Problem: paying milestone payments before entering in Phase II for a NCE for pain?
-
Direct hERG inhibition assay was negative, but Anaxomics safety analysis showed that QTc prolongation was likely to occur.
-
Extensive in vivo analysis suggested cardiotoxicity.
-
Sponsor saved money and chose other candidates

Prediction Results: New Indications

Please, contact us here to request more information.


